What this panel supports, and what it does not

The guided case supports a heme-reactive substance or lysed red cells over intact hematuria, because the blood pad is positive while sediment RBC is 0 to 2/HPF, within this case laboratory's local interval, with no casts. It does not establish hemoglobinuria or myoglobinuria specifically, and it does not rule out a small, patchy hematuria that a single field count could miss. Both remain possible; the panel argues against intact hematuria as the leading explanation without excluding it.

What the case depends on is local policy: what counts as a clinically significant discordance, whether a repeat is automatic or judgment-based, which confirmatory method (sulfosalicylic acid, quantitative protein or albumin, alternate blood method) your laboratory uses, and who is responsible for requesting medication or exposure history. These choices are not fixed here because a general audience cannot answer them; verify your own site's discrepant-result procedure before applying anything here on shift.

CLIA requires the laboratory to verify accuracy, precision, reportable range, and the suitability of a manufacturer's reference intervals before releasing nonwaived patient results on an unmodified FDA-cleared system, and requires documented control procedures with corrective action before reporting results when control criteria are not met. Those requirements are why checking QC and strip status is not an optional first step; it is the baseline the rest of the reasoning assumes was already met.

A discordant panel is a prompt to state what the evidence supports, check the preanalytical and analytical variables that could produce it, and follow your local algorithm, never a prompt to force the chemistry and the sediment into agreement by discounting one of them.